WO2022055276A1 - Marqueur de polymorphisme pour les gènes associés à la perte de cheveux chez la femme et son utilisation - Google Patents

Marqueur de polymorphisme pour les gènes associés à la perte de cheveux chez la femme et son utilisation Download PDF

Info

Publication number
WO2022055276A1
WO2022055276A1 PCT/KR2021/012290 KR2021012290W WO2022055276A1 WO 2022055276 A1 WO2022055276 A1 WO 2022055276A1 KR 2021012290 W KR2021012290 W KR 2021012290W WO 2022055276 A1 WO2022055276 A1 WO 2022055276A1
Authority
WO
WIPO (PCT)
Prior art keywords
base
seq
snp
nucleotide sequence
polynucleotide
Prior art date
Application number
PCT/KR2021/012290
Other languages
English (en)
Korean (ko)
Inventor
권오상
김종일
온정윤
손호영
Original Assignee
서울대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교 산학협력단 filed Critical 서울대학교 산학협력단
Publication of WO2022055276A1 publication Critical patent/WO2022055276A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • the present invention provides a single nucleotide polymorphism (SNP) marker composition for diagnosing or predicting female pattern alopecia, a composition for diagnosing or predicting female pattern alopecia comprising an agent for detecting or amplifying the SNP as an active ingredient, including the composition It relates to a kit for diagnosing or predicting female pattern alopecia and a method for providing information for diagnosing or predicting female pattern alopecia.
  • SNP single nucleotide polymorphism
  • female pattern alopecia is the most common hair loss disease in women. Although the cause of female pattern alopecia has not yet been clearly elucidated, it is assumed that it is caused by a combination of genetic and environmental influences, like male pattern hair loss. To date, a significant amount of genes related to androgenetic alopecia and single nucleotide polymorphism (SNP) markers associated with the genes are known, and some genes (AR/EDA2R, 1p36.22, 2q35, 2q37.3, 3q25.1) are known.
  • SNP single nucleotide polymorphism
  • the present inventors identify the characteristics of genes and single nucleotide polymorphism (SNP) markers of the genes that are helpful in determining or diagnosing the risk of female pattern alopecia, and based on this, diagnose female pattern alopecia or predict the risk of occurrence
  • SNP single nucleotide polymorphism
  • Another object of the present invention is to provide a composition for diagnosing or predicting female pattern alopecia.
  • Another object of the present invention is to provide a kit for diagnosing or predicting female pattern alopecia.
  • Another object of the present invention is to provide an information providing method for diagnosing or predicting female pattern alopecia.
  • the present invention provides a single nucleotide (SNP) for diagnosing or predicting female pattern alopecia, comprising at least one polynucleotide selected from the group consisting of polynucleotides of the following (1) to (20). polymorphism) a marker composition is provided:
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 1 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 3 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 4 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 5 or a polynucleotide complementary thereto;
  • (6) a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 6 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 7 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 8 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 9 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 10 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or CA in the nucleotide sequence of SEQ ID NO: 11 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 12 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or A in the nucleotide sequence of SEQ ID NO: 13 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 14 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 15 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 16 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 17, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or A in the nucleotide sequence of SEQ ID NO: 18 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 19 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 20 or a polynucleotide complementary thereto.
  • the composition may further include one or more polynucleotides selected from the group consisting of polynucleotides of the following (1) to (150):
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 21 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 23 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 24 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or GTATAGCAT in the nucleotide sequence of SEQ ID NO: 25 or a polynucleotide complementary thereto;
  • (6) a polynucleotide comprising a SNP in which the 101st base is T or A in the nucleotide sequence of SEQ ID NO: 26 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 27 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or T in the nucleotide sequence of SEQ ID NO: 28 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 29 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 30 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or G in the nucleotide sequence of SEQ ID NO: 31 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or T in the nucleotide sequence of SEQ ID NO: 32 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or T in the nucleotide sequence of SEQ ID NO: 33 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 34 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or G in the nucleotide sequence of SEQ ID NO: 35 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 36 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is TACAA or T in the nucleotide sequence of SEQ ID NO: 37 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or A in the nucleotide sequence of SEQ ID NO: 38 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or C in the nucleotide sequence of SEQ ID NO: 39 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or C in the nucleotide sequence of SEQ ID NO: 40 or a polynucleotide complementary thereto;
  • (21) a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 41 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 43 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 44 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or C in the nucleotide sequence of SEQ ID NO: 45 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or G in the nucleotide sequence of SEQ ID NO: 46 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 47 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is TCAAA or T in the nucleotide sequence of SEQ ID NO: 48 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 49 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 50 or a polynucleotide complementary thereto;
  • (31) a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 51 or a polynucleotide complementary thereto;
  • (32) a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 52 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or T in the nucleotide sequence of SEQ ID NO: 53 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 54 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 55 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 56 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 57 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or T in the nucleotide sequence of SEQ ID NO: 58 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or C in the nucleotide sequence of SEQ ID NO: 59 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 60 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 61 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 62, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 63 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 64, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 65 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or G in the nucleotide sequence of SEQ ID NO: 66 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 67 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 69, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or C in the nucleotide sequence of SEQ ID NO: 70 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 71, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or GA in the nucleotide sequence of SEQ ID NO: 72 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 73, or a polynucleotide complementary thereto;
  • polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 74 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 75 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 76, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 77 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 78, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is TG or T in the nucleotide sequence of SEQ ID NO: 79 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 80, or a polynucleotide complementary thereto;
  • (61) a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 81, or a polynucleotide complementary thereto;
  • (62) a polynucleotide comprising a SNP in which the 101st base is T or A in the nucleotide sequence of SEQ ID NO: 82, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 83, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 84, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 85 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 86, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or G in the nucleotide sequence of SEQ ID NO: 87, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 88, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 89, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or T in the nucleotide sequence of SEQ ID NO: 90 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 91 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or G in the nucleotide sequence of SEQ ID NO: 92, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 93, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 94 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 95 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 96 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is AC or A in the nucleotide sequence of SEQ ID NO: 97 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 98, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or G in the nucleotide sequence of SEQ ID NO: 99 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or C in the nucleotide sequence of SEQ ID NO: 100 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or A in the nucleotide sequence of SEQ ID NO: 101 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is AT or T in the nucleotide sequence of SEQ ID NO: 102 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 103, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or C in the nucleotide sequence of SEQ ID NO: 104, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 105, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 106, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or C in the nucleotide sequence of SEQ ID NO: 107, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 109, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 110 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or A in the nucleotide sequence of SEQ ID NO: 111 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 113, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 114, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 115, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 116, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 120 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or A in the nucleotide sequence of SEQ ID NO: 121 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is CT or C in the nucleotide sequence of SEQ ID NO: 122, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 123, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or A in the nucleotide sequence of SEQ ID NO: 124 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 125, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 126 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or C in the nucleotide sequence of SEQ ID NO: 127, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 128 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 129, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 130 or a polynucleotide complementary thereto;
  • (111) a polynucleotide comprising a SNP in which the 101st base is T or G in the nucleotide sequence of SEQ ID NO: 131 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or G in the nucleotide sequence of SEQ ID NO: 133, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or G in the nucleotide sequence of SEQ ID NO: 134 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 135, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 136, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 137, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is TG or T in the nucleotide sequence of SEQ ID NO: 138, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 139, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is TCTCA or T in the nucleotide sequence of SEQ ID NO: 141, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 142, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or T in the nucleotide sequence of SEQ ID NO: 143, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 144, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or A in the nucleotide sequence of SEQ ID NO: 145, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 146, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 147, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or A in the nucleotide sequence of SEQ ID NO: 148, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 149, or a polynucleotide complementary thereto;
  • polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 150 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 151 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 152, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is GTC or G in the nucleotide sequence of SEQ ID NO: 153, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or T in the nucleotide sequence of SEQ ID NO: 154, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 155, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 156 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or A in the nucleotide sequence of SEQ ID NO: 157, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 158, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or A in the nucleotide sequence of SEQ ID NO: 159, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 161, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 163, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 164, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 165, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 166 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 167, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 168, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or C in the nucleotide sequence of SEQ ID NO: 170, or a polynucleotide complementary thereto.
  • the female pattern alopecia may be for Koreans, but is not limited thereto.
  • the present invention provides a composition for diagnosing or predicting female pattern alopecia, comprising as an active ingredient an agent for detecting or amplifying one or more SNPs selected from the group consisting of single nucleotide polymorphisms (SNPs) of the following (1) to (20) to provide:
  • SNPs single nucleotide polymorphisms
  • SNP in which the 101st nucleotide is T or C in the nucleotide sequence of SEQ ID NO: 15;
  • SNP in which the 101st nucleotide is G or A in the nucleotide sequence of SEQ ID NO: 20.
  • the agent for detecting the SNP may be a probe capable of detecting one or more SNPs selected from the group consisting of the SNPs of (1) to (20), but is limited thereto. it's not going to be
  • the agent for amplifying the SNP may be a primer set capable of amplifying one or more SNPs selected from the group consisting of the SNPs of (1) to (20) above. It is not limited.
  • the composition may further include an agent for detecting or amplifying one or more SNPs selected from the group consisting of SNPs of the following (1) to (150):
  • SNP in which the 101st nucleotide is A or G in the nucleotide sequence of SEQ ID NO: 21;
  • SNP in which the 101st nucleotide is C or G in the nucleotide sequence of SEQ ID NO: 35;
  • SNP in which the 101st nucleotide in the nucleotide sequence of SEQ ID NO: 141 is TCTCA or T;
  • the agent for detecting the SNP may be a probe capable of detecting one or more SNPs selected from the group consisting of the SNPs of (1) to (150), but is limited thereto. it's not going to be
  • the agent for amplifying the SNP may be a primer set capable of amplifying one or more SNPs selected from the group consisting of the SNPs of (1) to (150), but this It is not limited.
  • the present invention provides a kit for diagnosing or predicting female pattern alopecia comprising the composition according to the present invention.
  • the kit may be an RT-PCR kit or a microarray chip kit, but is not limited thereto.
  • the present invention is a step of diagnosing female pattern alopecia or predicting that female pattern alopecia will occur when SNP satisfying any one or more selected from the group consisting of the following (1) to (20) is identified from a nucleic acid sample isolated from an individual It provides an information providing method for diagnosing or predicting female pattern alopecia, including:
  • the present invention provides a step of diagnosing female pattern alopecia or predicting that female pattern alopecia will occur when SNP satisfying any one or more selected from the group consisting of (1) to (20) is identified from a nucleic acid sample isolated from an individual It provides a method for diagnosing or predicting female pattern alopecia, including.
  • the information providing method is a method for diagnosing female pattern alopecia or predicting that female pattern alopecia will occur when a SNP satisfying any one or more selected from the group consisting of the following (1) to (150) is identified from a nucleic acid sample isolated from an individual. It may further include steps:
  • the SNP is sequencing, exome sequencing, microarray hybridization, allele specific PCR, dynamic allele hybridization technique (dynamic allele-specific hybridization), PCR extension analysis, and may be identified by one or more methods selected from the group consisting of Taqman technique, but is not limited thereto.
  • a single nucleotide polymorphism (SNP) marker composition for diagnosing or predicting female pattern alopecia of the present invention a composition for diagnosing or predicting female pattern alopecia comprising an agent for detecting or amplifying the SNP as an active ingredient, including the composition
  • the kit for diagnosing or predicting female pattern alopecia and the information providing method for diagnosing or predicting female pattern alopecia there is an effect of predicting and diagnosing the risk of female pattern alopecia for each individual in advance.
  • FIG. 1 is a diagram showing a ROC (receiver operating characteristic) curve derived based on the female pattern alopecia risk value according to the present invention.
  • the present inventors obtained a gene from a healthy woman without a history other than female pattern alopecia, and confirmed that a specific gene and thousands of single nucleotide polymorphism (SNP) present on the gene are related to female pattern alopecia did.
  • SNP single nucleotide polymorphism
  • association analysis using the SNP markers of the test group/control group was performed to detect the genotype associated with female pattern alopecia, and 170 statistically significantly significantly observed in female pattern alopecia patients compared with the normal control group of SNPs were selected (see Example 3).
  • the present invention can provide a SNP (single nucleotide polymorphism) marker composition for diagnosing or predicting female pattern alopecia, comprising one or more polynucleotides selected from the group consisting of polynucleotides of the following (1) to (20):
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 1 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 3 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 4 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 5 or a polynucleotide complementary thereto;
  • (6) a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 6 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 7 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 8 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 9 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 10 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or CA in the nucleotide sequence of SEQ ID NO: 11 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 12 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or A in the nucleotide sequence of SEQ ID NO: 13 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 14 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 15 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 16 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 17, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or A in the nucleotide sequence of SEQ ID NO: 18 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 19 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 20 or a polynucleotide complementary thereto.
  • composition may further include one or more polynucleotides selected from the group consisting of polynucleotides of the following (1) to (150):
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 21 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 23 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 24 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or GTATAGCAT in the nucleotide sequence of SEQ ID NO: 25 or a polynucleotide complementary thereto;
  • (6) a polynucleotide comprising a SNP in which the 101st base is T or A in the nucleotide sequence of SEQ ID NO: 26 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 27 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or T in the nucleotide sequence of SEQ ID NO: 28 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 29 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 30 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or G in the nucleotide sequence of SEQ ID NO: 31 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or T in the nucleotide sequence of SEQ ID NO: 32 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or T in the nucleotide sequence of SEQ ID NO: 33 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 34 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or G in the nucleotide sequence of SEQ ID NO: 35 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 36 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is TACAA or T in the nucleotide sequence of SEQ ID NO: 37 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or A in the nucleotide sequence of SEQ ID NO: 38 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or C in the nucleotide sequence of SEQ ID NO: 39 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or C in the nucleotide sequence of SEQ ID NO: 40 or a polynucleotide complementary thereto;
  • (21) a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 41 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 43 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 44 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or C in the nucleotide sequence of SEQ ID NO: 45 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or G in the nucleotide sequence of SEQ ID NO: 46 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 47 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is TCAAA or T in the nucleotide sequence of SEQ ID NO: 48 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 49 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 50 or a polynucleotide complementary thereto;
  • (31) a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 51 or a polynucleotide complementary thereto;
  • (32) a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 52 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or T in the nucleotide sequence of SEQ ID NO: 53 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 54 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 55 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 56 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 57 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or T in the nucleotide sequence of SEQ ID NO: 58 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or C in the nucleotide sequence of SEQ ID NO: 59 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 60 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 61 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 62, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 63 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 64, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 65 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or G in the nucleotide sequence of SEQ ID NO: 66 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 67 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 69, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or C in the nucleotide sequence of SEQ ID NO: 70 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 71, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or GA in the nucleotide sequence of SEQ ID NO: 72 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 73, or a polynucleotide complementary thereto;
  • polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 74 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 75 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 76, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 77 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 78, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is TG or T in the nucleotide sequence of SEQ ID NO: 79 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 80, or a polynucleotide complementary thereto;
  • (61) a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 81, or a polynucleotide complementary thereto;
  • (62) a polynucleotide comprising a SNP in which the 101st base is T or A in the nucleotide sequence of SEQ ID NO: 82, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 83, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 84, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 85 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 86, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or G in the nucleotide sequence of SEQ ID NO: 87, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 88, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 89, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or T in the nucleotide sequence of SEQ ID NO: 90 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 91 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or G in the nucleotide sequence of SEQ ID NO: 92, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 93, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 94 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 95 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 96 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is AC or A in the nucleotide sequence of SEQ ID NO: 97 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 98 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or G in the nucleotide sequence of SEQ ID NO: 99 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or C in the nucleotide sequence of SEQ ID NO: 100 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or A in the nucleotide sequence of SEQ ID NO: 101 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is AT or T in the nucleotide sequence of SEQ ID NO: 102 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 103, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or C in the nucleotide sequence of SEQ ID NO: 104, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 105, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 106, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or C in the nucleotide sequence of SEQ ID NO: 107, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 109, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 110 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or A in the nucleotide sequence of SEQ ID NO: 111 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 113, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 114, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 115, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 116, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 120 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or A in the nucleotide sequence of SEQ ID NO: 121 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is CT or C in the nucleotide sequence of SEQ ID NO: 122, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 123, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or A in the nucleotide sequence of SEQ ID NO: 124 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 125, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 126 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or C in the nucleotide sequence of SEQ ID NO: 127, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 128 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 129, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 130 or a polynucleotide complementary thereto;
  • (111) a polynucleotide comprising a SNP in which the 101st base is T or G in the nucleotide sequence of SEQ ID NO: 131 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or G in the nucleotide sequence of SEQ ID NO: 133, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or G in the nucleotide sequence of SEQ ID NO: 134 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 135, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 136, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 137, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is TG or T in the nucleotide sequence of SEQ ID NO: 138, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 139, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is TCTCA or T in the nucleotide sequence of SEQ ID NO: 141, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 142, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or T in the nucleotide sequence of SEQ ID NO: 143, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 144, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or A in the nucleotide sequence of SEQ ID NO: 145, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 146, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 147, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or A in the nucleotide sequence of SEQ ID NO: 148, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 149, or a polynucleotide complementary thereto;
  • polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 150 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 151 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 152, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is GTC or G in the nucleotide sequence of SEQ ID NO: 153, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or T in the nucleotide sequence of SEQ ID NO: 154, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 155, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is G or A in the nucleotide sequence of SEQ ID NO: 156 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or A in the nucleotide sequence of SEQ ID NO: 157, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 158, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or A in the nucleotide sequence of SEQ ID NO: 159, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 161, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 163, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is C or T in the nucleotide sequence of SEQ ID NO: 164, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 165, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or G in the nucleotide sequence of SEQ ID NO: 166 or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 167, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is T or C in the nucleotide sequence of SEQ ID NO: 168, or a polynucleotide complementary thereto;
  • a polynucleotide comprising a SNP in which the 101st base is A or C in the nucleotide sequence of SEQ ID NO: 170, or a polynucleotide complementary thereto.
  • polynucleotide refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in the form of single or double strands. Unless otherwise limited, known analogs of natural nucleotides that hybridize to nucleic acids in a manner analogous to naturally occurring nucleotides are also included.
  • DNA is composed of four bases: adenine (A), guanine (G), cytosine (C), and thymine (T), and RNA consists of uracil (U) instead of thymine (Uracil, U).
  • A forms a hydrogen bond with T or U
  • C forms a hydrogen bond with a G base
  • the relationship between these bases is called 'complementary'.
  • complementary is sufficient to selectively hybridize a targeting moiety in a nucleic acid molecule to a target (eg, an EDN gene) under certain hybridization or annealing conditions, specifically physiological conditions (in a cell). It means complementary, which may have one or more mismatched nucleotide sequences, and has a meaning encompassing both substantially complementary and perfectly complementary, and more specifically means completely complementary.
  • polymorphism refers to the occurrence of two or more alternative sequences or alleles (or alleles) within a genetically determined population
  • SNP single nucleotide polymorphism
  • a single base (A, T, C, or G) in the genome refers to the diversity of DNA sequences that occur between members of a species or between paired chromosomes of an individual.
  • the term “marker” refers to a nucleotide sequence used as a reference point when identifying genetically unspecifiedly related loci.
  • the term also applies to nucleic acid sequences complementary to marker sequences, such as nucleic acids used as primer sets capable of amplifying the marker sequence.
  • the location on the genetic map of a genetic marker is referred to as a genetic locus.
  • the term “gene marker” may be used interchangeably with terms such as a DNA marker, a biomarker, and a molecular marker.
  • the marker can be usefully used because it can rapidly distinguish traits without being affected by the cultivation environment or growth period of crops.
  • a genetic marker is a method of indicating polymorphism between individuals by targeting differences in the nucleotide sequence of DNA, which is the essence of genetic phenomena. (Restriction Fragment Length Polymorphism) probes or SCAR (Sequence Characterized Amplified Region) markers are being used.
  • allele means that one gene present at the same locus of a homologous chromosome has different traits.
  • the term “gynecomastia” refers to the characteristics of an individual for which the risk is to be predicted or diagnosed, and the phenotype that can be measured using the SNP marker according to the present invention includes without limitation, but preferably It may be female pattern alopecia. Since the SNP marker of the present invention can predict and diagnose the risk of female pattern alopecia, it can also give information about changes in the scalp and hair in contact with the active ingredient.
  • diagnosis refers to determining a subject's susceptibility to a particular disease or condition, determining whether a subject currently has a particular disease or disorder, It is a concept that includes both determining the prognosis of an affected subject, or therametrics (eg, monitoring the condition of an object to provide information on treatment efficacy).
  • the female pattern alopecia may be for Koreans, but is not limited thereto.
  • the present invention provides an agent for detecting or amplifying one or more SNPs selected from the group consisting of SNPs (single nucleotide polymorphisms) of the following (1) to (20) as an active ingredient, Gynegenetic alopecia diagnosis or to provide a composition for prediction:
  • SNP in which the 101st nucleotide is T or C in the nucleotide sequence of SEQ ID NO: 15;
  • SNP in which the 101st nucleotide is G or A in the nucleotide sequence of SEQ ID NO: 20.
  • the composition may further include an agent for detecting or amplifying one or more SNPs selected from the group consisting of SNPs of the following (1) to (150):
  • SNP in which the 101st nucleotide is A or G in the nucleotide sequence of SEQ ID NO: 21;
  • SNP in which the 101st nucleotide is C or G in the nucleotide sequence of SEQ ID NO: 35;
  • SNP in which the 101st nucleotide in the nucleotide sequence of SEQ ID NO: 141 is TCTCA or T;
  • nucleotide sequences of SEQ ID NO: 1 to SEQ ID NO: 170 the base corresponding to the SNP position according to the present invention is represented by r, and based on the SNP position, 100 nt of the sequence in the 5' direction, the 3' direction The sequence 100 nt is indicated.
  • nucleotide sequence of SEQ ID NO: 1 indicates the SNP position as r, and the nucleotide sequence of 100 nt in length is indicated on both sides based on this, and a total length of 201 nt is indicated.
  • nucleotide sequence of SEQ ID NO: 1 to SEQ ID NO: 170 is used for the purpose of specifying the position of the SNP in an individual, in particular, a human, and therefore, the length or the indicated range of the nucleotide sequence of SEQ ID NO: 1 to SEQ ID NO: 170
  • the present invention is not limited by the
  • the term “detection” means measuring and confirming the presence or absence of a target substance (SNP in the present invention), or measuring and confirming a change in the presence level of a target substance am. Therefore, the “agent” according to the present invention is an agent capable of specifically binding to and recognizing the site containing the SNP according to the present invention or amplifying the site containing the SNP, specifically, at the site containing the SNP. It may be a set of primers capable of specifically amplifying a probe capable of specifically binding, a polynucleotide including a region including the SNP, or a polynucleotide complementary thereto.
  • primer is a short single-stranded oligonucleotide that serves as a starting point of DNA synthesis.
  • the primer specifically binds to a polynucleotide as a template under suitable buffer and temperature conditions, and DNA polymerase adds a nucleoside triphosphate having a base complementary to the template DNA to the primer to link it. is synthesized
  • a primer generally consists of a sequence of 15 to 30 bases, and the melting temperature (Tm) at which it binds to the template strand varies depending on the base composition and length.
  • the sequence of the primer does not need to have a completely complementary sequence to a part of the base sequence of the template, but it is sufficient if it hybridizes with the template and has sufficient complementarity within the range to perform the intrinsic function of the primer. Therefore, in the present invention, the primer set, which is the detection agent according to the present invention, can be easily designed with reference to the nucleotide sequence of the cDNA or genomic DNA of the SNP site.
  • a primer for detecting SNP does not need to have a perfectly complementary sequence to each gene sequence, and as long as it has a length and complementarity suitable for the purpose of measuring the amount of mRNA by amplifying a specific section of mRNA or cDNA through DNA synthesis Suffice.
  • the primers for the amplification reaction consist of a set (pair) that complementarily binds to the template (or sense) and the opposite side (antisense) of both ends of a specific section of the mRNA to be amplified.
  • the term “probe” refers to an RNA having a length of several to hundreds of base pairs that can specifically bind to mRNA, cDNA (complementary DNA), DNA, etc. of a specific gene. Alternatively, it refers to a polynucleotide fragment such as DNA, and is labeled so that the presence or absence of the target mRNA or cDNA to be bound, the expression level, etc. can be checked. Probe selection and hybridization conditions can be appropriately selected according to techniques known in the art. The probe may be used in a diagnostic method for detecting an allele (or allele, allele).
  • the diagnostic methods include detection methods based on hybridization of nucleic acids, such as Southern blot, and may be provided in a form previously bound to a substrate of a DNA chip in a method using a DNA chip.
  • the primer or probe may be chemically synthesized using a phosphoramidite solid support synthesis method or other well-known methods.
  • the primer or probe may be variously modified according to methods known in the art within the range that does not interfere with hybridization with the polynucleotide to be detected.
  • modifications include methylation, encapsulation, substitution of one or more homologues of natural nucleotides, and modifications between nucleotides, such as uncharged linkages such as methyl phosphonates, phosphoesters, phosphoroamidates, carbamates, etc. ) or charged linkages (eg, phosphorothioate, phosphorodithioate, etc.), and binding of a labeling material using fluorescence or enzymes.
  • uncharged linkages such as methyl phosphonates, phosphoesters, phosphoroamidates, carbamates, etc.
  • charged linkages eg, phosphorothioate, phosphorodithioate, etc.
  • the probe may further have a reporter conjugated to its 5' end.
  • the reporter is FAM (6-carboxyfluorescein), Texas red (texas red), fluorescein (fluorescein), fluorescein chlorotriazinyl (fluorescein chlorotriazinyl), HEX (2',4',5',7'-tetrachloro -6-carboxy-4,7-dichlorofluorescein), rhodamine green, rhodamine red, tetramethylrhodamine, fluorescein isothiocyanate (FITC), oregon green, Alexa alexa fluor, JOE (6-Carboxy-4',5'-Dichloro-2',7'-Dimethoxyfluorescein), ROX (6-Carboxyl-X-Rhodamine), TET (Tetrachloro-Fluorescein), TRITC ( It may be any one or more selected from the group consisting of
  • the probe may further have a quencher conjugated to its 3' end.
  • the quencher is TAMRA, BHQ (black hole quencher) 1, BHQ2, BHQ3, NFQ (nonfluorescent quencher), dabcyl, Eclipse, DDQ (deep dark quencher), Blackberry Quencher (Blackberry Quencher), Iowa black (Iowa black) ) may be any one or more selected from the group consisting of, but any known material that can be used as a quencher in the art may be used.
  • the present invention may provide a kit for diagnosing or predicting female pattern alopecia comprising the composition according to the present invention.
  • the kit can diagnose or predict the risk of female pattern alopecia by confirming the SNP marker for diagnosis or prediction of female pattern alopecia through amplification, or by confirming the presence of a specific allele, for example, a minor allele in the SNP marker.
  • the kit may be an RT-PCR kit or a microarray chip kit, but is not limited thereto.
  • the RT-PCR kit may include each primer set capable of amplifying a nucleic acid comprising the SNP site, other test tubes or other suitable containers, reaction buffers, deoxynucleotides (dNTPs), Taq-polymerization enzymes and enzymes such as reverse transcriptase, DNase, RNAse inhibitors, DEPC-water, sterile water, and the like.
  • dNTPs deoxynucleotides
  • Taq-polymerization enzymes and enzymes such as reverse transcriptase, DNase, RNAse inhibitors, DEPC-water, sterile water, and the like.
  • a primer set specific for a gene used as a quantitative control may be included together.
  • the microarray chip kit may include a microarray having a substrate on which a nucleic acid including the SNP site is immobilized.
  • the microarray may be composed of a conventional microarray except that the polynucleotide, primer set, or probe of the present invention is included.
  • Hybridization of nucleic acids on microarrays and detection of hybridization results are well known in the art.
  • a nucleic acid sample is labeled with a fluorescent substance, for example, a label capable of generating a detectable signal including a substance such as Cy3 and Cy5, and then hybridized on a microarray and the labeling substance
  • a hybridization result can be detected by detecting a signal generated from
  • the present invention when SNPs satisfying any one or more selected from the group consisting of the following (1) to (20) are identified from a nucleic acid sample isolated from an individual, the present invention is diagnosed as female pattern alopecia or female pattern alopecia It is possible to provide an information providing method for diagnosing or predicting female pattern alopecia or a method for diagnosing or predicting female pattern alopecia, including predicting that this will occur:
  • the information providing method is a method for diagnosing female pattern alopecia or predicting that female pattern alopecia will occur when a SNP satisfying any one or more selected from the group consisting of the following (1) to (150) is identified from a nucleic acid sample isolated from an individual. It may further include steps:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne les éléments suivants : une composition de marqueur de polymorphisme nucléotidique unique (SNP) pour le diagnostic ou la prédiction de la perte de cheveux chez la femme ; une composition pour le diagnostic ou la prédiction de la perte de cheveux chez la femme comprenant un agent détectant ou amplifiant le SNP en tant qu'ingrédient actif ; un kit pour le diagnostic ou la prédiction de la perte de cheveux chez la femme comprenant la composition ; et un procédé pour fournir des informations pour le diagnostic ou la prédiction de la perte de cheveux chez la femme. La présente invention peut être utilisée pour prédire, à l'avance, et détecter le risque de développer une perte de cheveux chez la femme de façon individuelle, et en outre, sur la base des informations obtenues par la présente invention, il est possible de développer des dispositifs médicaux, des médicaments, des cosmétiques, des ingrédients actifs, et autres, personnalisés individuellement, qui peuvent prévenir les symptômes de la perte de cheveux chez la femme, atténuer ces symptômes, ou empêcher l'aggravation de ces symptômes.
PCT/KR2021/012290 2020-09-11 2021-09-09 Marqueur de polymorphisme pour les gènes associés à la perte de cheveux chez la femme et son utilisation WO2022055276A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200116690A KR102464776B1 (ko) 2020-09-11 2020-09-11 여성형 탈모증 관련 유전자 다형성 마커 및 이의 용도
KR10-2020-0116690 2020-09-11

Publications (1)

Publication Number Publication Date
WO2022055276A1 true WO2022055276A1 (fr) 2022-03-17

Family

ID=80630306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/012290 WO2022055276A1 (fr) 2020-09-11 2021-09-09 Marqueur de polymorphisme pour les gènes associés à la perte de cheveux chez la femme et son utilisation

Country Status (2)

Country Link
KR (1) KR102464776B1 (fr)
WO (1) WO2022055276A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008055196A2 (fr) * 2006-10-31 2008-05-08 Genizon Biosciences Inc. Carte génétique des gènes humains associés à la calvitie masculine
KR102151713B1 (ko) * 2019-07-15 2020-09-04 주식회사 테라젠바이오 탈모의 위험도를 예측하기 위한 조성물, 마이크로어레이, 및 키트, 및 이를 이용한 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2108704A1 (fr) 2008-04-07 2009-10-14 Life & Brain GmbH Alopecie androgène
EP2519653A4 (fr) 2009-12-31 2013-07-10 Univ Columbia Procédés pour la détection et la régulation de l'alopécie en aires, et de cohortes de gènes de celle-ci
KR101533395B1 (ko) * 2013-01-21 2015-07-08 이상열 단일 염기 다형성을 이용한 개체간의 유사도 산출 방법 및 시스템
KR101933601B1 (ko) * 2017-04-25 2019-04-01 연세대학교 산학협력단 탈모 예측용 snp 프라이머 및 이의 용도
KR102102200B1 (ko) * 2018-07-09 2020-04-21 (주)메디젠휴먼케어 단일염기다형성을 이용한 탈모 표현형 예측 방법
KR102061317B1 (ko) 2018-11-22 2020-01-02 주식회사 다우진유전자연구소 단일염기다형성을 이용한 탈모 예측용 키트 및 이를 이용한 탈모 예측 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008055196A2 (fr) * 2006-10-31 2008-05-08 Genizon Biosciences Inc. Carte génétique des gènes humains associés à la calvitie masculine
KR102151713B1 (ko) * 2019-07-15 2020-09-04 주식회사 테라젠바이오 탈모의 위험도를 예측하기 위한 조성물, 마이크로어레이, 및 키트, 및 이를 이용한 방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
L. YIP; S. ZALOUMIS; D. IRWIN; G. SEVERI; J. HOPPER; G. GILES; S. HARRAP; R. SINCLAIR; J. ELLIS: "Gene‐wide association study between the aromatase gene (CYP19A1) and female pattern hair loss", BRITISH JOURNAL OF DERMATOLOGY, JOHN WILEY, HOBOKEN, USA, vol. 161, no. 2, 29 April 2009 (2009-04-29), Hoboken, USA, pages 289 - 294, XP071134892, ISSN: 0007-0963, DOI: 10.1111/j.1365-2133.2009.09186.x *
REDLER SILKE, MESSENGER ANDREW G., BETZ REGINA C.: "Genetics and other factors in the aetiology of female pattern hair loss", EXPERIMENTAL DERMATOLOGY, BLACKWELL MUNSGAARD, COPENHAGEN; DK, vol. 26, no. 6, 1 June 2017 (2017-06-01), COPENHAGEN; DK , pages 510 - 517, XP055909818, ISSN: 0906-6705, DOI: 10.1111/exd.13373 *
RUI WENLONG, SHENG YOUYU, HU RUIMING, MIAO YING, HAN YUMEI, GUO XIA, QI SISI, XU FENG, XU JINHUA, YANG QINPING: "Association of Single Nucleotide Polymorphisms in the CYP19A1 Gene with Female Pattern Hair Loss in a Chinese Population", DERMATOLOGY, S. KARGER AG, CH, vol. 231, no. 3, 17 September 2015 (2015-09-17), CH , pages 239 - 244, XP055909817, ISSN: 1018-8665, DOI: 10.1159/000433597 *

Also Published As

Publication number Publication date
KR20220034957A (ko) 2022-03-21
KR102464776B1 (ko) 2022-11-09

Similar Documents

Publication Publication Date Title
WO2015068957A1 (fr) Méthode de détection de plusieurs acides nucléiques cibles utilisant des sondes de blocage et des sondes de détection
WO2012081898A2 (fr) Marqueur destiné à établir un pronostic du cancer de l'estomac et procédé d'établissement d'un pronostic du cancer de l'estomac
WO2011055916A2 (fr) Procédé de détection de la méthylation de gènes marqueurs de méthylation spécifiques du cancer du côlon pour le diagnostic du cancer du côlon
WO2015023146A1 (fr) Méthode de détection de lésions précancéreuses
WO2012070861A2 (fr) Biomarqueur de méthylation spécifique du cancer de l'estomac pour le diagnostic du cancer de l'estomac
WO2011105654A1 (fr) Sonde y et sa variante, puce à adn, nécessaire et méthode d'analyse de gènes utilisant la sonde y et sa variante
WO2021182881A1 (fr) Multiples biomarqueurs pour le diagnostic du cancer du sein et utilisation associée
WO2018038352A2 (fr) Biomarqueur d'auto-anticorps permettant de diagnostiquer la démence et méthode de diagnostic de la démence utilisant celui-ci
WO2020105873A1 (fr) Kit de diagnostic et procédé d'identification de séquence complète du génome utilisant l'amplification complète du génome de coronavirus alpha humain
WO2022055276A1 (fr) Marqueur de polymorphisme pour les gènes associés à la perte de cheveux chez la femme et son utilisation
WO2015167087A1 (fr) Procédé pour prédire le risque d'une spondylarthrite ankylosante à l'aide de variants du nombre de copies d'adn
CN101180408A (zh) 用遗传多态性分析评估发生肺癌的风险的方法
WO2019168261A1 (fr) Procédé d'analyse qualitative ou quantitative de génotype mutant et kit de pcr en temps réel pour la mise en œuvre de ce procédé
WO2011139032A2 (fr) Composition d'amorces permettant d'amplifier une région génique présentant diverses modifications dans un gène cible
WO2014157825A1 (fr) Procédé et trousse d'analyse d'allèles hla utilisant une pcr multiplex rapide
WO2019135477A2 (fr) Procédé de diagnostic de maladie de tsutsugamushi au moyen de gène multicopie
WO2022220575A1 (fr) Marqueur de polymorphisme génétique permettant de déterminer la couleur de la peau et son utilisation
WO2014175604A2 (fr) Composition permettant de diagnostiquer la dystrophie cornéenne d'avellino et méthode de diagnostic de la dystrophie cornéenne d'avellino
WO2010140827A2 (fr) Trousse de détection automatique d''allèles hla par réaction en chaîne de la polymérase en temps réel
WO2012150818A2 (fr) Procédé pour prédire un risque de leucémie myéloïde chronique, et kit de diagnostic utilisant celui-ci
EP3895170A1 (fr) Procédé de détection d'un analyte cible dans un échantillon à l'aide d'une fonction en forme de s pour un ensemble de données de pente
WO2023106680A1 (fr) Procédé et système de prédiction de changement du ton de chair d'une ordonnance contenant de la vitamine c
WO2021034034A1 (fr) Méthode de détection d'une anomalie chromosomique à l'aide d'informations concernant la distance entre des fragments d'acide nucléique
WO2016003047A1 (fr) Procédé pour analyser des informations sur un gène de fœtus à partir du sang ou du plasma d'une femme enceinte, à l'aide d'une pcr numérique
WO2011081501A2 (fr) Marqueur moléculaire pour la discrimination de ms3 (gène de stérilité mâle nucléaire-génique) et procédé de certification utilisant ledit marqueur

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21867141

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21867141

Country of ref document: EP

Kind code of ref document: A1